drugset
Drugs / Autologous Anti-H3.3K27M TCR-expressing T-cells
last change Jan 2026 re-read 3 minutes ago

Autologous Anti-H3.3K27M TCR-expressing T-cells

Cell therapy

Developed for
diffuse midline glioma, H3 K27M-mutant
Investigated by
Alliance for Cancer Gene Therapy · Parker Institute for Cancer Immunotherapy · The V Foundation · University of California, San Francisco

Trials 1

today NCT05478837 · Ph 1
202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05478837 Jul 2023 → Jan 2026 diffuse midline glioma, H3 K27M-mutant University of California, San Francisco Terminated No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Autologous Anti-H3.3K27M TCR-expressing T-cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT05478837 ↗
Modality Cell therapy “genetically modified cells called KIND T cells” NCT05478837 ↗
Route Intravenous “single intravenous (IV) infusion” NCT05478837 ↗